Physician profile
Thomas J Lambert
NPI 1225252489
$1,416.31
in general payments reported to CMS, 2019-2025
12 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $51.03 · 2021: $477 · 2022: $106 · 2023: $61.97 · 2024: $98.89 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $420.07 | 2020-2025 | |
| Abbvie INC. | $274.30 | 2019-2021 | |
| Leo Pharma INC. | $239.82 | 2021-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $156.55 | 2019 | |
| Galderma Laboratories, L.P. | $149.84 | 2021 | |
| Janssen Biotech, INC. | $46.84 | 2021 | |
| Pfizer INC. | $41.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $27.05 | 2025 | |
| Celgene Corporation | $17.21 | 2019 | |
| Epi Health, LLC | $16.60 | 2021 | |
| Allergan, INC. | $14.20 | 2022 | |
| Merck Sharp & Dohme LLC | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.